RCR Bladder Cancer Radiotherapy Audit 2016

Slides:



Advertisements
Similar presentations
بسم الله الرحمن الرحيم ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Advertisements

North Tees University Hospital Audit of T1 Rectal Cancers September 2013 – August 2014 Nicola Maguire Teaching fellow General Surgery 12/09/2014.
Merseyside and Cheshire Cancer Network HEPATO BILIARY MULTIDISCIPLINIARY TEAM MEETING Referral to Specialist HPB (Liver) MDT, University Hospital, Aintree,
Implementing a Cold Chain System Ensuring Cost Effectiveness and Reducing Unused Dispensed Chemotherapy Sue Hull Helen Wilkinson.
Radiotherapy for Kidney cancer
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
23/09/2010 Urology Network Meeting Prostate and Bladder Cancer RLU/BGH Joint Clinic Presented by: Dr Z Malik.
CTOS Soft Tissue Sarcoma of the Extremity Comparison of Conformal Post-operative Radiotherapy (CRT) and Intensity Modulated Radiotherapy (IMRT)
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.
Achieving safety and quality in MCCN chemotherapy services.
AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
بسم الله الرحمن الرحيم. Adult Hodgkin’s Lymphoma in the Eastern Part of Libya Dr. M.Mangoush, R. Nafo, S.Kardah, M.Letaiwish, S.Kardah, F.Bodabous, S.Ebkhatra.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
NMDT (%)Path (%)NOS (%)CNS (%) Weston Area Health  70.5  5.7  66.3  Yeovil District Hospital  54.9  22.9  82.9  University Hospitals.
Assessment of radiotherapy set-up error for limb sarcoma using electronic portal imaging (EPI) Wendy Ella, Eleanor Gill, Anna Cassoni, Beatrice Seddon.
Delivering clinical research to make patients, and the NHS, better Urology SSG 22nd April 2015 Research Wendy Cook, Research Delivery Manager Dr Mohini.
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
*Be brief, yet thorough enough to allow recoding of the data fields from the text only! * Use accepted abbreviations from Abstractor’s Manual Appendix.
Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
SCTS Education day “Radiotherapy in 2016”
National Clinical Pathway for suspected and confirmed lung cancer:
Bladder Cancer R. Zenhäusern.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Dr. Malhar Patel DNB (Radiation Oncology)
Oesophago–Gastric Cancer Audit
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND URETER
What is lung cancer? Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These abnormal cells do not carry out the functions.
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Oesophago–Gastric Cancer
Results of Definitive Radiotherapy in Anal Canal Carcinoma
AUTHORS: DR VERNA VANDERPUYE,: DR JOEL YARNEY,: FRANCIS ASAMOAH:
National Oesophago–Gastric Cancer Audit 2015.
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Bladder Cancer and Prostatic Cancer
HANA Audit Update for SSG
Creating the perfect text…
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Fig. 1c: Cystoprostatectomy specimen
Oesophago–Gastric Cancer
Oesophago–Gastric Cancer
Pathway for patients with suspected Breast Cancer
National Lung Cancer Audit
Management of Vulval Melanoma
Pathway for patients with suspected Skin Cancer
Pathway for patients with suspected Upper GI (OG) Cancer
New developments in oncological treatment for Stage 3 NSCLC
Chemotherapy Services in England: Ensuring quality and safety
Results from the first National Lung Cancer Organisational Audit.
Protocol Summary National Wilms Tumor Study Group (NWTS)
Pathway for patients with suspected colorectal cancer
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
2018 National Mesothelioma Audit
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Pathway for patients with suspected Breast Cancer
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Clinical and Epidemiological Profile of children receiving
Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.
Squamous cell carcinoma pathway update
SCC MDT Service Evaluation
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Presentation transcript:

RCR Bladder Cancer Radiotherapy Audit 2016 Dr Sarah Treece Peterborough City Hospital

Audit Questions Written by: Formatted by: Sarah Treece Mohini Varughese Formatted by: Karl Drinkwater Similar to previous RCR Audits e.g. lung cancer

Audit Format Piloted in several RT departments Electronic submission Drop down boxes/ tick boxes to minimise free text Data input does not need to be done by clinical staff

Audit Format 60-70 questions Time required per patient = 20-25 min if radically treated 10 min if palliative treatment Some information only required for first patient submitted by a centre

Data for collection – all patients DOB, male/ female WHO Performance status Pathology Cell subtype Grade TNM staging Dates of TURBT and histology report

Data for collection – radical patients Staging modalities Pelvic staging CT chest and upper tract imaging Use of PET MDTs Local and specialist network Was a cystectomy offered?

Data for collection – radical patients Neo-adjuvant chemotherapy Doses and drugs used Number of cycles Date of first cycle Reasons for not giving

Data for collection - radiotherapy Fractionation used Referral date for RT Dates of RT Total days If prolonged, compensation used (if any)

Data for collection - radiotherapy Use of radiosensitiser Doses and drugs used Reasons for not giving

Data for collection - radiotherapy Target definition Margins used Set up error Technique OARs and constraints used

Data for collection - radiotherapy Immobilisation used Compensation for bladder filling Verification Toxicity recording Treated in a trial?

Data for collection F/U plans Frequency Imaging Urology/ oncology/ both

Any comments?

Thank you To those who piloted the audit Dr Ian Fraser, Royal Devon and Exeter Hospital Dr Rob Huddart, Royal Marsden Dr Abigail Hollingdale, Peterborough City Hospital Dr Jonathan McAleese, Belfast City Hospital Prof Heather Payne, UCL And to Karl Drinkwater for formatting the questions